Skip to content

PolitiKit

Lobbying by Optimi Health Corp: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Optimi Health Corp

Meetings this Parliament
2
With MPs
2
Since Nov 2021
2
Active registrations
1

Most recent reported meeting: Oct 22, 2026.

Registrations in effect

Consultant In effect since Sep 8, 2026

Consultant Leah Young of Bluesky Strategy Group

Consultant lobbyists

  • Leah Young Former public office holder

    Formerly Senior Advisor, Parliamentary Affairs, N/A, Opposition House Leader's Office (2022–2024)

    Formerly Members' Assistant- MP Brad Vis, N/A, House of Commons (2021–2022)

    Formerly Junior Writer, N/A, Opposition Leader's Office (2020–2021)

Institutions they may lobby: Canadian International Trade Tribunal (CITT), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Safety Canada (PS), Senate of Canada

What they're lobbying on (3)
  • Regulation around clinical trials for psilocybin
  • C-286 An act to amend the Controlled Drugs and Substances Act and the Good and Drugs Act. Discuss proposed amendments related to the regulation of psilocybin and psilocin for medical purposes, including their treatment under the Narcotic Control Regulations and priority review of eligible new drug submissions.
  • C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access). Discuss proposed amendments to the Food and Drugs Act related to special access to therapeutic products, including pre-approved access pathways, clinical decision-making, evidence requirements, and administrative processes.

Registration 959031-387923-1. Look it up in the official Registry

Reported meetings

Spreadsheet

  • Reported by Leah Young · Consultant

    C-286

    Regulation around clinical trials for psilocybin Read more

    C-286 An act to amend the Controlled Drugs and Substances Act and the Good and Drugs Act. Discuss proposed amendments related to the regulation of psilocybin and psilocin for medical purposes, including their treatment under the Narcotic Control Regulations and priority review of eligible new drug submissions.

    Official report

  • Reported by Leah Young · Consultant

    C-286

    C-286 An act to amend the Controlled Drugs and Substances Act and the Good and Drugs Act. Discuss proposed amendments related to the regulation of psilocybin and psilocin for medical purposes, including their treatment under the Narcotic Control Regulations and priority review of eligible new drug submissions. Read more

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.